Print

Active Biotech AB Year-end Report, January - December 2009

2010-02-11

 

  • Laquinimod ― Phase III program proceeding according to plan  

  • 57-57 ― exploratory clinical trial in progress 

  • RhuDex(TM) ― additional preclinical studies to be conducted in 2010 

  • ANYARA ― Phase III trials proceeding according to plan 

  • TASQ ― primary endpoint met in clinical Phase II 

  • ISI ― project proceeding according to plan 

  • Net sales of SEK 10.8 M (53.5) 

  • Operating loss of SEK 219.6 M (loss: 184.6)  

  • Loss after tax of SEK 224.0 M (loss: 181.6) 

  • Loss per share for the period amounted to SEK 3.81 (loss: 3.66) 


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54


Hans Kolam

Active Biotech AB

CFO

(Corp. Reg. No. 556223-9227)

Tel: +46 (0)46-19 20 44

Box 724, 220 07 Lund


Tel: +46 (0)46-19 20 00

This report is also available at www.activebiotech.com

Fax +46 (0)46-19 11 00



pdfActive Biotech AB Year-end Report, January – December 2009



Back